ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Carew et al. reported that the treatment of different CML cell lines and primary CML cells expressing wild-type and Imatinib-resistant mutant forms of BCR-ABL, including T315I, with an histone deacetylase inhibitor (suberoylanilide hydroxamic acid (SAHA)) induced autophagy and that its inhibition (by using Chloroquine) potentiated the anti-neoplastic effects of SAHA [323].